Blue Matter Blog
December 13, 2018
Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face. Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology. In this installment, we introduce the complex array …
December 7, 2018
Gene therapy has made significant advances over the past few years. However, those therapeutic advances have not been accompanied by spectacular commercial successes, at least not yet. This raises a simple question: When will gene therapy fully realize its commercial potential? We explored that question with a distinguished panel on November 7, 2018 at the …
By pressing the “Accept Cookies” button, the user accepts all Cookies on the Website. View our Cookie Statement.